Polyphosphazene immunoadjuvants: Historical perspective and recent advances

The development of successful vaccines has been increasingly reliant on the use of immunoadjuvants - additives, which can enhance and modulate immune responses to vaccine antigens. Immunoadjuvants of the polyphosphazene family encompass synthetic biodegradable macromolecules, which attain in vivo activity via antigen delivery and immunostimulation mechanisms. Over the last decades, the technology has witnessed evolvement of next generation members, expansion to include various antigens and routes of administration, and progression to clinical phase. This was accompanied by gaining important insights into the mechanism of action and the development of a novel class of virus-mimicking nano-assemblies for antigen delivery. The present review evaluates in vitro and in vivo data generated to date in the context of latest advances in understanding the primary function and biophysical behavior of these macromolecules. It also provides an overview of relevant synthetic and characterization methods, macromolecular biodegradation pathways, and polyphosphazene-based multicomponent, nanoparticulate, and microfabricated formulations.

Automated summary

The development of successful vaccines increasingly relies on the use of immunoadjuvants, particularly those from the polyphosphazene family. These molecules, through antigen delivery and immunostimulation mechanisms, have shown in vivo activity and have evolved to include various antigens and routes of administration, progressing to clinical phases. This advancement has also led to the development of a novel class of virus-mimicking nano-assemblies for antigen delivery.